Our People
Dr. Allan E. Rubenstein
Advisory Board
Dr. Allan E. Rubenstein is a highly experienced public company board director, a successful entrepreneur, and a respected doctor. In medicine and science, he is a neurologist known for his pioneering work on research and treatment of neurofibromatosis, (NF), a rare genetic disorder, and has become expert due to his commercial interests in genomics, ocular conditions and treatments, medical devices, and women’s health.
Dr. Rubenstein served as Vice-Chairman and Lead Independent Director for The Cooper Companies (NYSE: COO). He successfully founded a mobile CT and MRI scanning company that was eventually sold. He subsequently founded and served as CEO of NexGenix Pharma and joined the board of Bioclinica (Nasdaq:BIOC). Dr. Rubenstein recently joined the board of Visioneering Technologies (VTI:ASX), a contact lens company, and is head of the Scientific Advisory Board for Coloursmith Labs Inc., a privately held company which has a unique technology for wavelength-filtering polymers for contact lenses.
Dr. Rubenstein is considered one of the world’s experts regarding NF. He started the first multidisciplinary clinic devoted to NF in the world at the Mount Sinai School of Medicine, which over the years became the model for more than 150 other NF clinics in the U.S., Europe, and South America. He also co-founded the Children’s Tumor Foundation and served as its medical director for more than two decades. Dr. Rubenstein is well-known for his expertise in advancing science through collaborations between the NIH, other government agencies, scientists, and donors. He is currently a Clinical Professor of Neurology and Pediatrics at NYU Medical Center. Dr. Rubenstein graduated from Cornell University and received his medical degree from Tufts University. He serves on the Advisory Board of the Tufts University Graduate Program in Biomedical Sciences.